How Peter Marks’ FDA departure is impacting pharma, biotech stocks

The abrupt resignation announcement that came late on Friday, March 28, from Peter Marks, who heads the U.S. FDA’s Center for Biologics Evaluation and Research, has sent reverberations throughout the pharma and biotech industries.

Marks, a well-respected hematologist oncologist who has